Irrus Investments

Novus Diagnostics develops a point-of-care diagnostic system for infectious diseases, including a sample-to-answer sepsis platform that rapidly detects and classifies pathogens in whole blood. The device provides automated pathogen identification within minutes from a blood sample, allowing healthcare providers to diagnose sepsis-related infections and initiate timely, cost-effective treatment.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

Bounce Insights is a digital consumer research platform and agency that links brands to active consumers through a mobile-app-based community. It blends research consultancy, data, and technology to deliver agile, robust quantitative insights, enabling brands—particularly in the consumer packaged goods, fast-moving consumer goods, and retail sectors—to access timely consumer data and make informed decisions.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.

FeelTect is a medical device company based in Galway, Ireland, founded in 2019, that develops and markets pressure sensing devices for compression therapy of venous leg ulcers. Its device measures and monitors sub-bandage pressure, enabling live readings and recorded data to support safe, effective, individualized treatment during and outside clinical settings, with the aim of ensuring correct compression levels and reducing healthcare burden.

Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

ByoWave is a company that specializes in creating inclusive gaming experiences through its innovative video game controller, the Proteus Controller. This modular controller is designed to accommodate both disabled and non-disabled gamers, featuring a unique 'snap and play' system that allows users to easily connect various components. ByoWave's approach enables gamers to customize their controller configurations online, facilitating sharing and collaboration within the gaming community. The Proteus Controller is compatible with popular gaming platforms, including Xbox and PC, ensuring a versatile solution for a diverse audience.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

Cinclus Pharma AG is a research-based biotech company focused on developing small molecules to treat gastric acid-related diseases, with a particular emphasis on gastroesophageal reflux disease (GERD). Their primary asset, X842, is designed to address severe erosive GERD and has undergone Phase I clinical trials. Additionally, the company is exploring a dual therapy treatment that combines an antibiotic targeting Helicobacter pylori bacteria. Cinclus Pharma AG operates from its headquarters in Basel, Switzerland.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

Gasgon Medical is a medical device company focused on enhancing intravenous (IV) infusion processes. It aims to improve patient safety and clinical efficiency by developing innovative devices that minimize risks such as Vascular Air Embolism. By supporting medical staff with better tools, Gasgon enables them to deliver superior patient care and outcomes.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

Using the latest in-house technology Allview Healthcare gives you access to leading Consultant and surgical services Rapid diagnosis and care. Currently the largest dermatology provider across Ireland, servicing both the HSE (State Health Provider) and the VHI (Ireland's largest private insurance company) A highly experienced management team and board of directors with both medical and technical professionals whose main aim is to ensure that patients receive the best care by the best consultant at the right time. We work hard to ensure our best practice, clinical governance and quality assurance is at its highest level thus leading to extremely high patient satisfaction.

Sigrid Therapeutics, based in Stockholm, Sweden, is a clinical-stage biotechnology company developing a new class of therapies that target lifestyle diseases by altering how the body digests food. It advances an engineered minerals platform and an ingested medical device designed to lower blood sugar in prediabetes, with the goal of preventing and treating chronic metabolic conditions. The lead program is a gut-acting therapy that aims to improve blood glucose regulation in individuals at risk of developing diabetes.

AniV8 is a company focused on developing clinical sensor technology aimed at diagnosing and monitoring diseases in companion animals. Its innovative technology utilizes clinical data in conjunction with a unique algorithm to assess motion, allowing veterinarians to evaluate the impact of osteoarthritis pain in pets. By providing a reliable method for monitoring common disease states, AniV8 enhances the ability of veterinary professionals to deliver effective care for animals.

Qualus develops sustainable technology for the leather industry. Its core product, Sferes, are polymer granules that help tanneries save water, lower production costs, and enhance leather quality. This enables industries such as automotive, footwear, and luxury goods to reduce their environmental footprint while minimizing waste.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

ProVerum Medical is a medtech company that develops minimally invasive devices to treat benign prostatic hyperplasia. Its technology enables safe and effective BPH treatment in a doctor's office or operating room in a less invasive, more patient-friendly manner than traditional approaches. The flexible delivery system uses 3-D geometry to engage prostate anatomy, delivering radial force to the prostatic lobes without cutting, piercing, or heating tissue, with precise deployment under direct visualization. The design is reversible for removal at any time and atraumatic, reducing bleeding and catheterization, and it offers a universal fit to accommodate diverse anatomies, enabling clinicians to treat urinary obstruction caused by prostate enlargement effectively.

OncoMark Limited, founded in 2007 and based in Dublin, Ireland, specializes in the discovery and development of diagnostics and therapeutic targets for cancer patients. As a spin-out from University College Dublin, the company focuses on creating companion diagnostic tests that enhance patient stratification in cancer drug development. These tests aid pharmaceutical companies in identifying patients for whom specific drugs are most likely to be effective, thereby improving clinical trial efficiency and success rates. OncoMark's portfolio includes tissue-based biomarker assays and a Biomarker Interpretation Workflow platform that automates various analyses, such as survival assessments and interpretation of immunohistochemistry staining. The company's diagnostic tests cover major cancer types, including breast, colorectal, prostate, and melanoma, and are supported by significant EU research and development funding. Led by CEO Dr. Mairin Rafferty, OncoMark is committed to improving treatment outcomes and quality of life for cancer patients.

ProVerum Medical is a medtech company that develops minimally invasive devices to treat benign prostatic hyperplasia. Its technology enables safe and effective BPH treatment in a doctor's office or operating room in a less invasive, more patient-friendly manner than traditional approaches. The flexible delivery system uses 3-D geometry to engage prostate anatomy, delivering radial force to the prostatic lobes without cutting, piercing, or heating tissue, with precise deployment under direct visualization. The design is reversible for removal at any time and atraumatic, reducing bleeding and catheterization, and it offers a universal fit to accommodate diverse anatomies, enabling clinicians to treat urinary obstruction caused by prostate enlargement effectively.

Adama Innovations Ltd. is a company based in Dublin, Ireland, focused on developing nanotechnology solutions for advanced manufacturing. Established in 2010 as a spin-out from the CRANN nanotechnology institute at Trinity College Dublin, Adama Innovations specializes in creating high-resolution nanoscale probes fabricated from diamond. These probes are designed for use in atomic force microscopy, enabling precise imaging, measurement, and manipulation at the nanoscale. The company’s innovative technology allows for the creation of micro-patterns on ultra-hard materials, which can be applied in various industries, including medical device fabrication, labeling, and anti-counterfeiting. Additionally, Adama Innovations offers a range of products, including diamond sharp cones and flare-shaped probes, to enhance capabilities in metrology and precision engineering.

Embo Medical, located at the National University of Ireland, is focused on developing innovative medical devices for vascular embolization. The company is creating the Caterpillar, a groundbreaking one-shot embolization device designed to enhance the efficiency and safety of peripheral vascular embolization procedures. This device aims to significantly reduce procedural times, enabling physicians to perform embolizations in a more cost-effective manner. With approximately 180,000 such procedures conducted annually worldwide, Embo Medical is positioned to make a meaningful impact in the medical field by improving patient outcomes and streamlining medical practices.

Wattics is a Dublin-based company that specializes in energy analytics software aimed at combating climate change. The firm provides a cloud-based data analytics and business intelligence platform tailored for energy consultants, analysts, and managers. By transforming traditional methods of energy management, Wattics enables users to move beyond static spreadsheets to dynamic, actionable insights that facilitate better cost control and asset management. The platform offers compatibility with various meter manufacturers, renewable energy sources, environmental sensors, and IoT devices, featuring advanced machine learning to detect energy abnormalities. Wattics' services include the COMPOSER and MAESTRO plans, which allow energy professionals to create custom formulas for energy efficiency projects and fully brand their analytics services. This innovative approach helps users acquire and retain customers through detailed saving and insight reports, ultimately creating new revenue streams. Founded in 2011 by Antonio Ruzzelli, Wattics has expanded its support operations to New York, Treviso, and Berlin, enhancing its global reach in the energy management market.